Prevention of gallstone formation: Constipation, diarrhea, headache, nausea, dizziness, vomiting, upper respiratory tract infection, back pain, viral infection, fatigue, influenza-like symptoms, abdominal pain, musculoskeletal pain, dysmenorrhea, alopecia, sinusitis, flatulence.
Oral suspension: The evaluation of undesirable effects is based on the following frequency data: See Table 6.
Click on icon to see table/diagram/imageGastrointestinal disorders: In clinical trials, reports of pasty stools or diarrhoea during UDCA therapy were common. Very rarely, severe right upper abdominal pain has occurred during the treatment of PBC.
Hepatobiliary disorders: During treatment with UDCA, calcification of gallstones can occur in very rare cases.
During therapy of the advanced stages of PBC, in very rare cases decompensation of hepatic cirrhosis has been observed, which partially regressed after the treatment was discontinued.
Skin and subcutaneous tissue disorders: Very rarely, urticaria can occur.
View ADR Reporting Link
Sign Out